Braeburn Pharmaceuticals and Knight Therapeutics Announce Filing of New Drug Submission for PROBUPHINE(R) in Canada for Opioid Drug Dependence

PRINCETON, N.J. and MONTREAL, June 13, 2017 -- (Healthcare Sales & Marketing Network) -- Braeburn Pharmaceuticals, Inc. ("Braeburn") and Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading Canadian specialty pharmaceutical compan... Biopharmaceuticals, Drug Delivery, Regulatory Braeburn Pharmaceuticals, Knight Therapeutics, PROBUPHINE, buprenorphine
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news